The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 2, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2019.
10-Q for Q3 FY2018, filed Nov 2, 2018
The sections below describe the company as of the FY2017 annual report.
Develops and sells cancer medicines, including ZEJULA and VARUBI, to specialty distributors and specialty pharmacy providers.
10-K for FY2017, filed Feb 28, 2018We are a commercial-stage biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. Our…View ↗
To date, we have received regulatory approvals for the following products, which are currently marketed and sold in the U.S. and in certain…View ↗
The Company sells its products principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S. and…View ↗
TESARO sells mainly through specialty distributors and specialty pharmacy providers in the U.S. and EU, who resell its products to healthcare providers and patients.
10-K for FY2017, filed Feb 28, 2018The Company sells its products principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S. and…View ↗
8-K, filed Jan 24, 2019
As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission by TESARO, Inc., a Delaware…View ↗
8-K, filed Nov 1, 2018
Total Revenue, net, worldwide (FY) $258 to $265 million (previously $250 to $265 million)View ↗
8-K, filed Jul 18, 2018
On July 12, 2018, TESARO, Inc. (the “Company”) completed the sale to TerSera Therapeutics LLC (“TerSera”) of the Company’s rights to…View ↗
Marketed medicines
The older report describes rolapitant and niraparib as product candidates, with an application for oral rolapitant pending. The latest report lists ZEJULA and VARUBI/VARUBY as marketed products.
10-K for FY2014, filed Feb 25, 2015 10-K for FY2017, filed Feb 28, 2018We are an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. We acquire, in-license and…View ↗
To date, we have received regulatory approvals for the following products, which are currently marketed and sold in the U.S. and in certain…View ↗
The U.S. Food and Drug Administration, or FDA, approved ZEJULA® (niraparib) in March 2017 for the maintenance treatment of women with…View ↗
VARUBI® (rolapitant) is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced…View ↗
Immuno-oncology development
The older report describes antibody programs at lead-selection or preclinical stages. The latest report says its immuno-oncology antibodies are in clinical trials, while a dual-target candidate remains in preclinical research.
10-K for FY2014, filed Feb 25, 2015 10-K for FY2017, filed Feb 28, 2018· Immuno-Oncology Platform: PD-1, or programmed cell death protein 1, is a key immune checkpoint molecule that can limit T-cell-mediated…View ↗
TSR-042 (anti-PD-1): We initiated a Phase 1, dose escalation study of TSR-042 in March 2016. We have also initiated expansion cohorts in…View ↗
TSR-022 (anti-TIM-3): We initiated a Phase 1, dose escalation study of TSR-022 in July 2016, evaluating TSR-022 as a monotherapy and in…View ↗
TSR-033 (anti-LAG-3): We initiated a Phase 1, dose escalation study of TSR-033 in August 2017 in multiple tumor types. We plan to initiate…View ↗
We have initiated pre-clinical research for TSR-075, our bi-specific anti-PD-1/LAG-3 candidate.View ↗
Competes with AstraZeneca, Clovis Oncology, Pfizer, AbbVie, BeiGene, EMD Serono, Checkpoint Therapeutics, Hengrui, Roche, Merck, Heron Therapeutics, Helsinn, Sandoz, Glenmark Pharmaceuticals USA, Bristol-Myers Squibb, Novartis, Regeneron, Sanofi, Eli Lilly, and Incyte
10-K for FY2017, filed Feb 28, 2018In addition to ZEJULA, there are currently two other commercially available PARP inhibitors. AstraZeneca Plc’s LYNPARZATM (olaparib) was…View ↗
Loading...
